Pardes Biosciences, Inc.
PRDSDelisted Aug 31, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822711
Pardes Biosciences, Inc. was delisted on Aug 31, 2023; its insiders filed their last Form 4 on Aug 31, 2023; 59 institutions reported holding it in 13F filings for Q2 2023, worth $63.9M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 59
- Q2 2023, −1 vs. previous quarter
- 13F value
- $63.9M
- Reported value at the end of Q2 2023
- Superinvestors holding
- 0
- At the end of Q2 2023
Superinvestors holding PRDS, Q2 2023
No superinvestor reported holding PRDS at the end of Q2 2023.
Latest insider trades
Open-market purchases and sales by Pardes Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 (view filing)9:08 PM ET | Apr 5 | 1 day | Tananbaum James B. and 2 othersDirector, 10% Owner | PPurchase | +774.0K | $1.50 | +$1.16M | +9.7%8.77M after | |
| Apr 6, 2023 (view filing)9:08 PM ET | Apr 5 | 1 day | Tananbaum James B. and 2 othersDirector, 10% Owner | PPurchase | +774.0K | $1.50 | +$1.16M | +6.0%13.6M after | |
| Dec 12, 2022 (view filing) | Dec 8 | 4 days | Brusky Sean P.Chief Commercial Officer | PPurchase | +21.0K | $1.19 | +$25.0K | New position21.0K after | |
| Dec 7, 2022 (view filing) | Dec 5 | 2 days | Wiggans Thomas GChief Executive Officer | PPurchase | +12.5K | $1.09 | +$13.6K | +33.3%50.0K after | |
| Dec 5, 2022 (view filing)4:24 PM ET | Dec 1 | 4 days | Tananbaum James B. and 2 othersDirector, 10% Owner | PPurchase | +637.4K | $0.85 | +$541.8K | +5.2%12.8M after | |
| Dec 5, 2022 (view filing) | Dec 1-2 | 4 days | Wiggans Thomas GChief Executive Officer | PPurchase | +37.5K | $1.05 | +$39.4K | New position37.5K after | 2 lots |
| Dec 23, 2021 (view filing)4:52 PM ET | Dec 22 | 1 day | Tananbaum James B. and 4 othersDirector, 10% Owner | PPurchase | +325.0K | $10.00 | +$3.25M | New position325.0K after |
Top 10 13F holders, Q2 2023
The largest institutional positions in Pardes Biosciences, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Foresite Capital Management V, LLC | 10,811,887 | $19.6M | 14.29% | +773,952+7.7% | Added |
| VK Services, LLC | 6,151,766 | $11.1M | 1.27% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 3,902,434 | $7.06M | 4.63% | +578,373+17.4% | Added |
| BML Capital Management, LLC | 3,791,633 | $6.86M | 6.17% | −194,944−4.9% | Reduced |
| Tang Capital Management LLC | 1,945,206 | $3.52M | 0.52% | +1,645,206+548.4% | Added |
| Chescapmanager LLC | 1,672,379 | $3.03M | 0.73% | +5000.0% | Added |
| Vanguard Group Inc | 994,997 | $1.80M | 0.00% | −140,552−12.4% | Reduced |
| Goldman Sachs Group Inc | 838,362 | $1.52M | 0.00% | +22,166+2.7% | Added |
| Arena Capital Advisors, LLC- CA | 826,104 | $1.50M | 5.00% | −25,177−3.0% | Reduced |
| Western Standard LLC | 482,874 | $874.0K | 0.76% | +482,874 | New |